Purpose: To assess the outcome of 0.5 mg intravitreal ranibizumab injection (IRI) with HRT III Macular Edema Module in patients with clinically significant diabetic macular edema (CSME). Methods: 35 patients (35 eyes) with CSME undergoing IRI were included. HRT were performed at baseline and 1 month after the treatment. Macular edema index (MEI) of central macular zone was calculated. At baseline patients were grouped according to MEI values (mild to severe; groups 1 to 3). Results: 1 month after the IRI treatment, while group 3 showed statistically significant reduction in MEI values, group 1 and 2 did not show any significant changes. Conclusions: Patients with severe CSME benefit most from IRI. HRT may be a relatively simple method of documenting change in ME and we have proposed a very simple method of documenting change in macular edema. HRT Macular Edema Module may help in choosing the appropriate treatment for CSME based on the degree of macular thickening.